When viewing this topic in a different language, you may notice some differences in the way the content is structured, but it still reflects the latest evidence-based guidance.

Last reviewed: 19 Sep 2025
Last updated: 19 Mar 2025

Summary

Definition

History and exam

Key diagnostic factors

  • presence of risk factors
  • depressed mood
  • anhedonia
  • functional impairment

Other diagnostic factors

  • weight change
  • libido changes
  • sleep disturbance
  • changes in movement
  • low energy
  • excessive guilt
  • poor concentration
  • suicidal ideation
  • somatic symptoms
  • bipolar disorder excluded
  • substance abuse/medication side effects excluded
  • medical illness excluded
  • schizophrenia excluded

Risk factors

  • postnatal status
  • personal or family history of depressive disorder or suicide
  • history of an anxiety disorder, or anxiety symptoms
  • adverse childhood experiences
  • dementia
  • corticosteroid use
  • interferon use
  • oral contraceptive use
  • co-existing medical conditions
  • female sex
  • comorbid substance use
  • personality disorders
  • history of violent victimisation
  • obesity
  • older age (≥65 years)
  • separated/divorced marital status

Diagnostic investigations

1st investigations to order

  • clinical diagnosis
  • metabolic panel
  • FBC
  • thyroid function tests
  • Patient Health Questionnaire-2 (PHQ-2)
  • Patient Health Questionnaire-9 (PHQ-9)
  • Edinburgh Postnatal Depression Scale
  • Geriatric Depression Scale
  • Cornell Scale for Depression in Dementia

Investigations to consider

  • 24-hour free cortisol
  • vitamin B12
  • folic acid

Treatment algorithm

Contributors

Authors

Dean F. MacKinnon, MD

Associate Professor

Psychiatry and Behavioral Sciences

The Johns Hopkins Hospital

Baltimore

MD

Disclosures

DFM declares that he has no competing interests.

Acknowledgements

Dr Dean F. MacKinnon would like to gratefully acknowledge Dr Roger S. McIntyre, Dr Tonya Fancher, and Dr Richard Kravitz, the previous contributors to this topic.

Disclosures

RSM has received research funds from Stanley Medical Research Institute and National Alliance for Research on Schizophrenia and Depression (NARSAD). RSM is on the advisory board for AstraZeneca, Bristol-Myers Squibb, France Foundation, GlaxoSmithKline, Janssen-Ortho, Solvay/Wyeth, Eli Lilly, Organon, Lundbeck, Biovail, Pfizer, Shire, and Schering-Plough. RSM is on the Speakers Bureau for Janssen-Ortho, AstraZeneca, Eli Lilly, Lundbeck, Biovail, and Wyeth. RSM has received research grants from Eli Lilly, Janssen-Ortho, Shire, and AstraZeneca. RSM has received travel funds from Bristol-Myers Squibb. TF declares that she has no competing interests. RK has received research grants from Pfizer on non-depression-related topics.

Peer reviewers

Christopher Dowrick, BA MBChB MSc MD

Emeritus Professor

University of Liverpool

UK

Disclosures

CD has been reimbursed by Novartis for participating in an educational event.

Erin K. Ferenchick, MD

Center for Family and Community Medicine

Columbia University Medical Center

Upper Manhattan

NY

Disclosures

EKF declares that she has no competing interests.

Peer reviewer acknowledgements

BMJ Best Practice topics are updated on a rolling basis in line with developments in evidence and guidance. The peer reviewers listed here have reviewed the content at least once during the history of the topic.

Disclosures

Peer reviewer affiliations and disclosures pertain to the time of the review.

References

Our in-house evidence and editorial teams collaborate with international expert contributors and peer reviewers to ensure that we provide access to the most clinically relevant information possible.

Key articles

American Psychiatric Association. Diagnostic and statistical manual of mental disorders, 5th ed., text revision (DSM-5-TR). Washington, DC: American Psychiatric Publishing; 2022.

National Institute for Health and Care Excellence. Depression in adults: treatment and management. Jun 2022 [internet publication].Full text

American College of Physicians. Nonpharmacologic and pharmacologic treatments of adults in the acute phase of major depressive disorder: a living clinical guideline from the American College of Physicians. Feb 2023 [internet publication]..Full text

Reference articles

A full list of sources referenced in this topic is available here.

Use of this content is subject to our disclaimer